Shares of Cerulean Pharma Inc. (NASDAQ:DARE) hit a new 52-week low on Tuesday . The company traded as low as $2.60 and last traded at $2.60, with a volume of 19,817 shares changing hands. The stock had previously closed at $2.63.
Separately, ValuEngine upgraded Cerulean Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 22nd.
The firm’s 50 day moving average price is $3.10 and its 200 day moving average price is $4.10. The firm’s market capitalization is $7.52 million.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/31/cerulean-pharma-inc-dare-hits-new-52-week-low-at-2-60.html.
About Cerulean Pharma
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
What are top analysts saying about Cerulean Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerulean Pharma Inc. and related companies.